Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182812 | 0.92 | POLB (0.48) | POLBALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL3386016 | 0.76 | CACNB4 (0.46) | POLBALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL1148608 | 0.76 | NOTUM (0.56) | POLBALDH1A1KDM4ECYP2C19CYP3A4 | |
| SCHEMBL28576841 | 0.74 | SLC22A12 (0.50) | — | |
| SCHEMBL4178385 | 0.74 | F2R (0.50) | POLBALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL4316805 | 0.74 | GAA (0.46) | POLBALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL3386295 | 0.73 | ALDH1A1 (0.52) | POLBALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL30185538 | 0.73 | HDAC6 (0.52) | POLBALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL28580014 | 0.73 | HDAC6 (0.52) | POLBALDH1A1KDM4ECYP2C9CYP2C19 | |
| SCHEMBL6085966 | 0.71 | KCNQ3 (0.55) | NR1I2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-1806141-B1 | PAR-2 ANTAGONISTS | KOWA CO (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1806355-A1 | PROCESS FOR PRODUCTION OF (1,3-DISUBSTITUTED INDOLYL)- UREA DERIVATIVES, INTERMEDIATES THEREFOR, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Kowa Company Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806141-A1 | PAR-2 ANTAGONISTS | Kowa Company, Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | WEE1, WASF2, IDO1 | POLB 4577/4885NR1I2 3861/4885ALDH1A1 2230/4885 |
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | POLB 3605/4885NR1I2 905/4885ALDH1A1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.